Skip to content
DataLookout
Menu

Also listed under Myeloproliferative Disorders

ClinicalTrials.gov term: Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Chronic Myeloid Leukemia (CML) clinical trials

Get alerts when Chronic Myeloid Leukemia (CML) trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-22

What changed in the last 30 days

26 trials changed in the last 30 days: 3 stopped, 13 with notable changes, 10 with minor changes only.

  1. Stopped: HA-1 T TCR T Cell Immunotherapy · Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant Recruitment suspended Fred Hutchinson Cancer CenterPhase 1 NCT03326921
  2. Notable: Dasatinib in Combination With Ropeginterferon · Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Phase changed: Phase 2 → Phase 1/2 M.D. Anderson Cancer CenterPhase 1/2 NCT07269470
  3. Notable: ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML Primary completion pushed from Nov 1, 2026 to Jun 1, 2027 Marlise Luskin, MDPhase 1 NCT03595917
  4. Stopped: Two Step Haplo With Radiation Conditioning Recruitment suspended Thomas Jefferson UniversityPhase 2 NCT05031897
  5. Notable: APTBCy · Optimization of Post-transplantation Benadamustine and Cyclophosphamide · High-risk Myeloid Malignancies and a Partially Mismatched Donor Primary and study completion pushed from Dec 10, 2026 to Dec 10, 2027 St. Petersburg State Pavlov Medical UniversityPhase 2 NCT07238712
  6. Notable: ENABLE-2 · ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs Recruitment opened Enliven TherapeuticsPhase 3 NCT07905183
  7. Minor: VitaStem · Vitamin A and D Supplementation in Allogeneic HCT Enrollment closed, study ongoing St. Petersburg State Pavlov Medical UniversityPhase 2 NCT06508099
  8. Notable: Allogeneic iNKT Cell Therapy (agenT-797) After SCT Recruitment opened University of Wisconsin, MadisonPhase 1 NCT07758218
  9. Notable: ESTIMATION · Asciminib in Chronic Phase CML · T315I Mutations Enrollment reopened Thomas Ernst, Prof. Dr. med.Phase 2 NCT07789574
  10. Notable: ASC4Young · Asciminib Safety and Efficacy in Young · Chronic Myeloid Leukemia in the Gulf Region Start date pushed from Oct 29, 2026 to Dec 1, 2026 Novartis PharmaceuticalsNot specified NCT07681258
  11. Notable: Patient Characteristics, Co-Morbidities, and Treatment Patterns in Chronic Myeloid Leukemia Patients in Kuwait Start date pushed from Oct 30, 2026 to Jan 31, 2027 Novartis PharmaceuticalsNot specified NCT07454850
  12. Minor: Asciminib · Ph+ CML-CP Trial sites expanded: 34 → 39 locations Novartis PharmaceuticalsPhase 2 NCT07354074
  13. Minor: Asciminib · Chronic Myeloid Leukemia Enrollment closed, study ongoing Novartis PharmaceuticalsPhase 1/2 NCT04925479
  14. Minor: Asciminib Roll-over Study Trial sites expanded: 85 → 88 locations Novartis PharmaceuticalsPhase 4 NCT04877522
  15. Minor: ASC2ADHERE · Asciminib · Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany Trial sites expanded: 69 → 74 locations Novartis PharmaceuticalsNot specified NCT07549516
  16. Minor: K2SPIRIT · Risk of Second Primary Malignancies for Chronic Myeloid Leukaemia in the French Imatinib-based SPIRIT Trial Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Enrolling by Invitation Poitiers University HospitalNot specified NCT06646978
  17. Stopped: Hu8F4 · Advanced Hematologic Malignancies Trial terminated M.D. Anderson Cancer CenterPhase 1 NCT02530034
  18. Minor: Collecting Blood Samples From · and Without Cancer to Evaluate Tests for Early Cancer Detection Trial sites expanded: 747 → 751 locations Alliance for Clinical Trials in OncologyNot specified NCT05334069
  19. Minor: Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens · Hematologic Malignancies Start date changed from estimate of Nov 4, 2026 to Oct 28, 2026 National Cancer Institute (NCI)Phase 1 NCT06904066
  20. Notable: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT) Primary completion pushed from Sep 2026 to Sep 2027 University of FloridaPhase 1/2 NCT05322850
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-10-14 NCT07872709 Oral Tetrahydrouridine-Decitabine in Patients With Advanced Myeloproliferative Neoplasms John Mascarenhas new Phase 2
2026-09-10 NCT07814170 A Manualised Post-Traumatic Growth Intervention For People With Hematological Cancers In… University of West Attica new
2026-09-04 NCT07804901 Asciminib Frontline Risk Adapted Prof. Dr. med. Andreas Hochhaus new Phase 2

Active trials by phase

Early Phase 1
1
Phase 1
32
Phase 1/2
13
Phase 2
64
Phase 3
9
Phase 4
3
Not charted: 56 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Get alerts when Chronic Myeloid Leukemia (CML) trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free

Narrower conditions

Active trials